Cerlapirdine: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Cerlapirdine}} | |||
== | == Overview == | ||
Cerlapirdine | '''Cerlapirdine''' is a [[pharmaceutical drug]] that was investigated for its potential use in the treatment of [[cognitive disorders]], particularly those associated with [[Alzheimer's disease]]. It is classified as a [[selective serotonin receptor antagonist]], specifically targeting the [[5-HT6 receptor]]. | ||
== | == Mechanism of Action == | ||
Cerlapirdine functions by selectively inhibiting the [[5-HT6 receptor]], a subtype of the [[serotonin receptor]] that is predominantly found in the [[central nervous system]]. The blockade of this receptor is believed to enhance the release of [[acetylcholine]] and other neurotransmitters, which are crucial for [[cognitive function]]. This mechanism suggests potential benefits in improving [[memory]] and [[learning]] in patients with cognitive impairments. | |||
== | == Development and Research == | ||
Cerlapirdine was developed as part of a broader effort to find effective treatments for [[neurodegenerative diseases]]. Initial studies focused on its ability to improve cognitive deficits in preclinical models. However, despite promising early results, further clinical trials were necessary to establish its efficacy and safety in humans. | |||
== | == Clinical Trials == | ||
Clinical trials for cerlapirdine aimed to assess its impact on cognitive function in patients with [[Alzheimer's disease]]. These trials were designed to evaluate both the safety profile and the therapeutic potential of the drug. Unfortunately, the outcomes of these trials did not demonstrate significant improvements over existing treatments, leading to a halt in its development. | |||
[[Category: | == Chemical Structure == | ||
[[Category: | [[File:Cerlapirdine.svg|thumb|right|Chemical structure of cerlapirdine]] | ||
[[Category: | Cerlapirdine is characterized by its unique chemical structure, which allows it to selectively bind to the 5-HT6 receptor. The molecular design was optimized to enhance its specificity and minimize off-target effects. | ||
== Potential Applications == | |||
While cerlapirdine did not advance to become a marketed drug, the research surrounding its development contributed valuable insights into the role of 5-HT6 receptors in cognitive processes. This knowledge continues to inform ongoing research in the field of [[neuropharmacology]]. | |||
== Related Pages == | |||
* [[Alzheimer's disease]] | |||
* [[Serotonin receptor]] | |||
* [[Cognitive disorders]] | |||
* [[Neuropharmacology]] | |||
[[Category:Pharmaceutical drugs]] | |||
[[Category:Serotonin receptor antagonists]] | |||
[[Category:Experimental drugs]] | |||
Latest revision as of 03:59, 13 February 2025
Overview[edit]
Cerlapirdine is a pharmaceutical drug that was investigated for its potential use in the treatment of cognitive disorders, particularly those associated with Alzheimer's disease. It is classified as a selective serotonin receptor antagonist, specifically targeting the 5-HT6 receptor.
Mechanism of Action[edit]
Cerlapirdine functions by selectively inhibiting the 5-HT6 receptor, a subtype of the serotonin receptor that is predominantly found in the central nervous system. The blockade of this receptor is believed to enhance the release of acetylcholine and other neurotransmitters, which are crucial for cognitive function. This mechanism suggests potential benefits in improving memory and learning in patients with cognitive impairments.
Development and Research[edit]
Cerlapirdine was developed as part of a broader effort to find effective treatments for neurodegenerative diseases. Initial studies focused on its ability to improve cognitive deficits in preclinical models. However, despite promising early results, further clinical trials were necessary to establish its efficacy and safety in humans.
Clinical Trials[edit]
Clinical trials for cerlapirdine aimed to assess its impact on cognitive function in patients with Alzheimer's disease. These trials were designed to evaluate both the safety profile and the therapeutic potential of the drug. Unfortunately, the outcomes of these trials did not demonstrate significant improvements over existing treatments, leading to a halt in its development.
Chemical Structure[edit]
Cerlapirdine is characterized by its unique chemical structure, which allows it to selectively bind to the 5-HT6 receptor. The molecular design was optimized to enhance its specificity and minimize off-target effects.
Potential Applications[edit]
While cerlapirdine did not advance to become a marketed drug, the research surrounding its development contributed valuable insights into the role of 5-HT6 receptors in cognitive processes. This knowledge continues to inform ongoing research in the field of neuropharmacology.
